^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hematological Malignancies

    Related cancers:
    Apply
    Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype (NCT06863402)
    Phase 2
    Roswell Park Cancer Institute
    Not yet recruiting
    Last update posted :
    07/18/2025
    Initiation :
    09/01/2025
    Primary completion :
    04/01/2029
    Completion :
    04/01/2030
    PD-L1
    |
    Keytruda (pembrolizumab) • nemtabrutinib (MK-1026)
    Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene (NCT07069699)
    Phase 1/2
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    07/17/2025
    Initiation :
    09/19/2025
    Primary completion :
    09/19/2027
    Completion :
    09/19/2027
    BCL2
    |
    pidnarulex (CX-5461)
    Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer (NCT07046078)
    Phase 2
    Fred Hutchinson Cancer Center
    Not yet recruiting
    Last update posted :
    07/02/2025
    Initiation :
    07/01/2025
    Primary completion :
    06/30/2027
    Completion :
    06/30/2029
    CD33
    |
    cytarabine • idarubicin hydrochloride • fludarabine IV • Starasid (cytarabine ocfosfate)
    Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells (NCT07042438)
    Phase 2
    City of Hope Medical Center
    Not yet recruiting
    Last update posted :
    06/29/2025
    Initiation :
    01/17/2026
    Primary completion :
    04/13/2028
    Completion :
    04/13/2028
    BCL2
    |
    Yescarta (axicabtagene ciloleucel)
    Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients (NCT07039877)
    Phase 2
    Hospital Universitario Dr. Jose E. Gonzalez
    Recruiting
    Last update posted :
    06/26/2025
    Initiation :
    01/02/2025
    Primary completion :
    02/28/2026
    Completion :
    04/30/2026
    BCL2
    |
    Venclexta (venetoclax) • bortezomib • itraconazole
    PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM) (NCT06871176)
    Phase N/A
    University Health Network, Toronto
    Recruiting
    Last update posted :
    06/25/2025
    Initiation :
    04/22/2025
    Primary completion :
    03/04/2028
    Completion :
    03/04/2028
    CXCR4
    Phase I/II Clinical Trial Evaluating the Safety and Efficacy of Universal Donor CD33 CAR Natural Killer Cells for Treatment of Myeloid Leukemia (CD33 CAR NK) (NCT07026942)
    Phase 1/2
    Nationwide Children's Hospital
    Not yet recruiting
    Last update posted :
    06/18/2025
    Initiation :
    07/01/2025
    Primary completion :
    07/01/2031
    Completion :
    07/01/2037
    CD33
    |
    cytarabine
    Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab (MAVRiC) (NCT07024706)
    Phase 2
    AstraZeneca
    Not yet recruiting
    Last update posted :
    06/17/2025
    Initiation :
    09/30/2025
    Primary completion :
    11/30/2032
    Completion :
    11/30/2032
    BCL2
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    Study for Patients With Hairy Cell Leukemia to Test the Targeted Agent Tovorafenib in Combination With Rituximab and Compare the Combination With Current Standard Treatment (NCT06965114)
    Phase 1/2
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    06/11/2025
    Initiation :
    09/30/2025
    Primary completion :
    03/01/2030
    Completion :
    03/01/2030
    BRAF
    |
    Rituxan (rituximab) • cladribine • Ojemda (tovorafenib) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL (ACCELERATE) (NCT07013565)
    Phase 2
    New York Medical College
    Not yet recruiting
    Last update posted :
    06/10/2025
    Initiation :
    07/01/2025
    Primary completion :
    07/01/2029
    Completion :
    07/01/2030
    PD-L1
    |
    Opdivo (nivolumab) • Adcetris (brentuximab vedotin) • vinblastine
    Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations (NCT07012447)
    Phase 2
    yuejun Liu
    Recruiting
    Last update posted :
    06/10/2025
    Initiation :
    04/01/2025
    Primary completion :
    04/01/2027
    Completion :
    05/01/2028
    BCL2
    |
    Venclexta (venetoclax) • cytarabine • azacitidine
    CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia (NCT07008872)
    Phase N/A
    Qi deng
    Not yet recruiting
    Last update posted :
    06/06/2025
    Initiation :
    06/01/2025
    Primary completion :
    05/31/2027
    Completion :
    05/31/2027
    CD7
    Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML (NCT07007312)
    Phase 3
    Kura Oncology, Inc.
    Not yet recruiting
    Last update posted :
    06/05/2025
    Initiation :
    09/01/2025
    Primary completion :
    11/01/2031
    Completion :
    11/01/2031
    NPM1
    |
    Venclexta (venetoclax) • cytarabine • daunorubicin • ziftomenib (KO-539)
    Use of Venetoclax , AML , Sohag , Egypt (NCT06993883)
    Phase N/A
    Sohag University
    Completed
    Last update posted :
    05/29/2025
    Initiation :
    03/01/2023
    Primary completion :
    04/30/2025
    Completion :
    04/30/2025
    BCL2
    |
    Venclexta (venetoclax)
    A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia (NCT06986174)
    Phase 2
    Shayna Sarosiek, MD
    Not yet recruiting
    Last update posted :
    05/22/2025
    Initiation :
    08/01/2025
    Primary completion :
    10/01/2028
    Completion :
    10/01/2032
    MYD88 • CXCR4
    |
    TP53 mutation
    |
    Vonjo (pacritinib)
    A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma (NCT06939283)
    Phase 1/2
    Werewolf Therapeutics, Inc.
    Recruiting
    Last update posted :
    04/22/2025
    Initiation :
    04/01/2025
    Primary completion :
    08/01/2028
    Completion :
    08/01/2028
    PD-L1
    |
    WTX-330
    CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma (NCT06850285)
    Phase N/A
    Shanxi Bethune Hospital
    Recruiting
    Last update posted :
    02/27/2025
    Initiation :
    09/05/2025
    Primary completion :
    06/01/2028
    Completion :
    06/01/2028
    TNFRSF8
    Improving Genomic Profiling and Reducing Time to Cancer Treatment Via Targeted Use of Endoscopic Ultrasound (IMPROVED) (NCT06848738)
    Phase N/A
    Zealand University Hospital
    Enrolling by invitation
    Last update posted :
    02/27/2025
    Initiation :
    05/07/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2026
    BRAF
    Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ (NCT06846463)
    Phase 2
    Virginia Commonwealth University
    Not yet recruiting
    Last update posted :
    02/26/2025
    Initiation :
    06/30/2025
    Primary completion :
    07/31/2029
    Completion :
    07/31/2032
    BCL2 • NOTCH1 • MYD88 • CD79B • CD5
    |
    doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib)
    Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (NCT04240808)
    Phase 1
    University of Colorado, Denver
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/17/2020
    Primary completion :
    03/24/2023
    Completion :
    12/01/2025
    CD19
    |
    CD19 positive
    |
    UCD19 CAR T Cells
    Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study (NCT04269902)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/02/2021
    Primary completion :
    10/01/2028
    Completion :
    10/01/2028
    TP53 • IGH
    |
    TP53 mutation • IGH mutation
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab)
    Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma (NCI-2020-09704) (NCT04640779)
    Phase 1
    Mayo Clinic
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/08/2021
    Primary completion :
    08/15/2026
    Completion :
    08/15/2027
    XPO1
    |
    Xpovio (selinexor)
    TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT05507541)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/19/2023
    Primary completion :
    11/01/2026
    Completion :
    11/01/2027
    PD-L1 • ALK • BCL2 • BCL6 • IRF4
    |
    ALK positive
    |
    Keytruda (pembrolizumab) • maplirpacept (TTI-622) • ontorpacept (PF-07901800)
    A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization (NCT06547112)
    Phase 1
    Washington University School of Medicine
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/31/2024
    Primary completion :
    01/31/2026
    Completion :
    01/31/2026
    CD34
    |
    Aphexda (motixafortide)
    Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma (NCT03922724)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/18/2019
    Primary completion :
    06/30/2025
    Completion :
    06/30/2029
    ALK • HLA-B • HLA-C
    |
    ALK positive
    |
    Jakafi (ruxolitinib) • cyclophosphamide • sirolimus
    Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (SWOG S1608) (NCT03269669)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/23/2018
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    CD4
    |
    lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • prednisone • bendamustine • Ukoniq (umbralisib) • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous
    Acalabrutinib with or Without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT03516617)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/10/2018
    Primary completion :
    03/15/2030
    Completion :
    03/15/2031
    CD20 • CCND1 • CD5 • FCER2
    |
    Chr t(11;14)
    |
    Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia (IMGN632-0802) (NCT04086264)
    Phase 1/2
    AbbVie
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/06/2019
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    IL3RA
    |
    CD123 positive • IL3RA positive
    |
    Venclexta (venetoclax) • azacitidine • decitabine • pivekimab sunirine (PVEK)
    Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (NCT03041688)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/08/2018
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    TP53 • CD4
    |
    TP53 mutation • Chr del(17p) • TP53 wild-type
    |
    Venclexta (venetoclax) • azacitidine • decitabine • navtemadlin (KRT-232)
    QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (NCT03169790)
    Phase 1/2
    ImmunityBio, Inc.
    Withdrawn
    Last update posted :
    02/24/2025
    Initiation :
    12/01/2017
    Primary completion :
    01/01/2019
    Completion :
    12/23/2021
    CD20
    |
    CD20 positive
    |
    Avastin (bevacizumab) • Rituxan (rituximab) • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • oxaliplatin • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-061 • NK92-CD16-158V • cyclophosphamide intravenous
    Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia (T-LGLL) (NCT05141682)
    Phase 1/2
    Jonathan Brammer
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/29/2022
    Primary completion :
    08/15/2024
    Completion :
    12/31/2025
    CD8
    |
    STAT3 mutation
    |
    Onureg (azacitidine oral)
    CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) (NCT04318678)
    Phase 1
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/29/2020
    Primary completion :
    05/01/2025
    Completion :
    05/01/2026
    CD123 • IL3RA
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • mesna • CD123-CAR T cell therapy • cyclophosphamide intravenous
    Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111-218) (NCT05068440)
    Phase 2
    BeiGene
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    08/11/2021
    Primary completion :
    10/21/2025
    Completion :
    10/21/2025
    CD79B
    |
    CD79B mutation • CD79B mutation
    |
    Brukinsa (zanubrutinib)
    Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (A041703) (NCT03739814)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    05/08/2019
    Primary completion :
    02/01/2026
    Completion :
    02/01/2026
    ABL1 • BCR • CD22
    |
    CD22 positive
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (NCT00792948)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/01/2009
    Primary completion :
    06/01/2016
    Completion :
    01/06/2026
    ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (NCI#10057) (NCT02978625)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/27/2017
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    PD-L1 • ALK • NECTIN1
    |
    ALK positive • ALK negative
    |
    Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters (NCT06009926)
    Phase 2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    02/21/2025
    Initiation :
    12/04/2023
    Primary completion :
    11/01/2025
    Completion :
    11/01/2027
    GSTM1 • GSTT1
    Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health (AMPLIFY) (NCT04000880)
    Phase N/A
    University of Alabama at Birmingham
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    03/04/2020
    Primary completion :
    04/01/2025
    Completion :
    04/01/2025
    IL6 • TNFA • CRP
    Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies (NCT04959175)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/23/2021
    Primary completion :
    04/27/2027
    Completion :
    04/30/2027
    EGFR • IGH
    |
    cyclophosphamide • sirolimus • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous
    Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (19-C-0116) (NCT04002947)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/05/2019
    Primary completion :
    05/31/2026
    Completion :
    03/31/2030
    ALK • BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)
    A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (BP41072) (NCT04077723)
    Phase 1/2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/13/2019
    Primary completion :
    03/31/2027
    Completion :
    03/31/2027
    CD20 • CD19
    |
    CD20 expression • CD19 expression
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm) • englumafusp alfa (RG6076)